StreetAlpha.app
Home › Stocks › LIVN

LivaNova PLC (LIVN)

Healthcare
$91.92
▼ −0.56%
LAST CLOSE · NOV 17

LivaNova makes medical devices for heart and lung surgery and neuromodulation, including a system for treating sleep apnea. It last closed at $91.92 on Nov 17, down 0.56% on the day. The average 12-month price target from 4 analysts is $108.25 (+17.8% from the last close), with a high of $120.00 and a low of $90.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell).

AI Auto Pilots
Is LIVN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$1.5B
+11.7% vs a year ago
Net income
$196.1M
13.0% margin
EPS (diluted)
$3.49
Free cash flow
$129.0M
8.6% margin
Valuation
Market cap
$5.1B
55.1M shares
P/E
26.3
Price over 12 month EPS
Price to sales
3.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$563.5M
At Sep 30
Debt
$295.4M
At Sep 30
Shareholder equity
$1.4B
Shares outstanding
55.1M
At Oct 28
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $1.0B$1.0BFY2021FY2022: $1.0B$1.0BFY2022FY2023: $1.2B$1.2BFY2023FY2024: $1.3B$1.3BFY2024FY2025: $1.4B$1.4BFY2025

From LIVN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on LIVN in the past 90 days
Average 12-month target
$108.25
▲ 17.8% upside

Based on 4 analysts who set a price target on LIVN in the past 90 days. The average target is $108.25, with a high of $120.00 and a low of $90.00, compared with the last close of $91.92.

Low $90.00Avg $108.25High $120.00
Blue marker: last close $91.92
Highest target$120.00
Average target$108.25
Lowest target$90.00
Latest rating changes
BarclaysTarget raised
Nov 9Buy$105 → $120
BairdMaintained
Nov 5Buy$111
NeedhamTarget raised
Nov 4Buy$93 → $112
BarclaysInitiated
Oct 7Buy$105
Piper SandlerReiterated
Sep 2Buy$90
DateFirmActionRatingPrice target
Nov 9BarclaysTarget raisedBuy$105 → $120
Nov 5BairdMaintainedBuy$111
Nov 4NeedhamTarget raisedBuy$93 → $112
Oct 7BarclaysInitiatedBuy$105
Sep 2Piper SandlerReiteratedBuy$90
Loading…

Technical Analysis

LIVN · as of the Nov 17 close · updated after every close
Uptrend, nearing overbought

The stock is 7% above its 20 day and 12% above its 50 day average. It is 19% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 66), near overbought. The nearest support is the Pivot S1 at $91.15, and the nearest resistance the Pivot at $92.40.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityHigh, 3.5%/day
Key levels
$99.3852 week high+8.1%
$99.38Swing high (Nov 4)+8.1%
$93.16Pivot R1+1.3%
$92.40Pivot+0.5%
$91.92Last close
$91.15Pivot S1−0.8%
$85.9320 day average−6.5%
$80.7650 day average−12.1%
$80.69100 day average−12.2%
$78.41Swing low (Oct 30)−14.7%
$74.44200 day average−19.0%
$52.3752 week low−43.0%
Indicators
RSI (14)65.56Strong, overbought above 70Neutral
MACD3.60Above its signal lineBullish
Stochastic64.3Middle of its rangeNeutral
ADX (14)31.6Trending up
Williams %R-35.6Oversold below −80, overbought above −20Neutral
CCI (20)75.7Oversold below −100, overbought above 100Neutral
Rate of change+15.0%Change over 10 sessionsBullish
ATR (14)$3.23Typical daily range, 3.5% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for LIVN

What happened before

See how LIVN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow LIVN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How LIVN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in LIVN in the last 90 days.

Loading…

See today’s whale options flow across the market →

LIVN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲163 buying vs 129 selling
  • ▼Held by funds -16.2 pts
  • ▲Funds holding +20
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding330310+6.5%
In funds' top 1003−100.0%
Held by funds138.8%––
New / increased50 / 11352 / 120−5.2%
Reduced / sold out102 / 2784 / 39+4.9%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LIVN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LIVN is in one of them and how their past LIVN trades turned out.

LIVN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LIVN in an article yet. Here's the latest on the wider market.

About LivaNova

LivaNova is a medical device company based in Gloucester, UK. Its Cardiopulmonary business sells perfusion systems and related consumables used in surgery involving the heart and lungs. Its Neuromodulation business offers devices, including a system in development for treating sleep apnea. The company sells its products in the United States, Europe and other regions around the world.

Headquarters
Gloucester